Study S001089

Efficacy and Safety of Cagrilintide S.C. 2.4 mg in Combination With Semaglutide S.C. 2.4 mg (CagriSema S.C. 2.4 mg/2.4 mg) Once-Weekly in East Asian Participants With Overweight or Obesity

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT05813925
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 331
Start: 2023-04-03
Primary completion: 2025-01-17
Lead sponsor: Novo Nordisk A/S
Conditions: Obesity or Overweight
Interventions: DRUG:Cagrilintide; DRUG:Semaglutide; DRUG:Placebo Semaglutide
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1277-3764; REGISTRY:jRCT2031220734

Registered primary outcomes

Relative Change in Body Weight [From baseline (week 0) to end of treatment (week 68)]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0007530	Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial. Yamauchi T, The lancet. Diabetes & endocrinology	2026	Randomized trial	PMID 42009015 DOI	cites ClinicalTrials.gov:NCT05813925; registry reference DERIVED:42009015